1-tosyl-1,4,5,6-tetrahydro-7H-indol-7-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-tosyl-1,4,5,6-tetrahydro-7H-indol-7-one
• 英文别名: 1-(4-methylbenzenesulfonyl)-5,6-dihydro-4H-indol-7-one；1-(4-methylphenyl)sulfonyl-5,6-dihydro-4H-indol-7-one
• 化学式: C₁₅H₁₅NO₃S
• 分子量: 289.355
• InChiKey: XJANHUXWODOVIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  64.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-tosyl-1,4,5,6-tetrahydro-7H-indol-7-one 在 三溴化磷 作用下， 以 四氢呋喃 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 为溶剂， 反应 13.5h， 生成 7-bromo-1-(4-methylbenzenesulfonyl)-7-(trifluoromethyl)-5,6-dihydro-4H-indole
  参考文献：
  名称：

  FUSED PYRROLYL-SULFONAMIDE COMPOUNDS

  摘要：

  The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, (I) wherein A, R1, and R2are as defined in the description and claims. The present invention also relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutical acceptable carrier. The present invention also relates to the present compounds for use as a medicine and/or as diagnostics. The present invention also relates to the present compounds for use in the prevention and/or treatment of GPR17 mediated disorders, such as for example a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.

  公开号：

  WO2024115733A1
• 作为产物：
  描述：

  N-甲苯磺酰基氮杂环丙烷 在 aluminum oxide 、 N-碘代丁二酰亚胺 、 hydroxide 、 双氧水 、 silica gel 、 丙酸 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 四氯化碳 、 水 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 1-tosyl-1,4,5,6-tetrahydro-7H-indol-7-one
  参考文献：
  名称：

  δ-（磺酰基）氨基-α-环氧酮通过分子内共轭物加成至偶氮中间体而转化为双环酮吡咯。1-氮杂富烯迷迭香的双环酮吡咯核的合成

  摘要：

  δ-（磺酰基）氨基-α-环氧酮与二甲基肼的反应导致环化成吡咯烷稠合的β-羟基二甲基hydr。水解，甲磺酰化和消除得到二氢吡咯，其可以通过用NIS氧化而转化为磺酰基保护的酮吡咯。另外，用DBU处理可得到带有NH的酮吡咯。

  DOI：

  10.1016/0040-4039(96)00390-5

文献信息

• A novel necroptosis inhibitor—necrostatin-21 and its SAR study
  作者：Zhijie Wu、Ying Li、Yu Cai、Junying Yuan、Chengye Yuan

  DOI：10.1016/j.bmcl.2013.06.073

  日期：2013.9

  An initial structure-activity relationship study of the novel necroptosis inhibitor Nec-21 was described. Any changes of the tetracyclic scaffold were detrimental for the activity. Introduction of a substituent to 7 or 8 position (e.g., cyano or methoxy group, respectively), would increase the activity. The 7 and 8-position disubstituted compound 17b was 35-fold as potent as the lead, while EC50 reached 14 nM. (C) 2013 Elsevier Ltd. All rights reserved.
• Conversion of δ-(sulfonyl)amino-α-epoxy ketones to bicyclic ketopyrroles via intramolecular conjugate-addition to azoene intermediates. Synthesis of the bicyclic ketopyrrole core of the 1-azafulvene roseophllin
  作者：Seong Heon Kim、P.L Fuchs

  DOI：10.1016/0040-4039(96)00390-5

  日期：1996.4

  Reaction of δ-(sulfonyl)amino-α-epoxy ketones with dimethylhydrazine results in cyclization to pyrrolidine-fused β-hydroxy dimethylhydrazones. Hydrolysis, mesylation, and elimination affords dihydropyrroles which can be converted to sulfonyl-protected ketopyrroles via oxidation with NIS; alternatively, treatment with DBU affords NH bearing ketopyrroles.

  δ-（磺酰基）氨基-α-环氧酮与二甲基肼的反应导致环化成吡咯烷稠合的β-羟基二甲基hydr。水解，甲磺酰化和消除得到二氢吡咯，其可以通过用NIS氧化而转化为磺酰基保护的酮吡咯。另外，用DBU处理可得到带有NH的酮吡咯。
• FUSED PYRROLYL-SULFONAMIDE COMPOUNDS
  申请人：[en]REWIND THERAPEUTICS NV

  公开号：WO2024115733A1

  公开（公告）日：2024-06-06

  The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, (I) wherein A, R1, and R2are as defined in the description and claims. The present invention also relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutical acceptable carrier. The present invention also relates to the present compounds for use as a medicine and/or as diagnostics. The present invention also relates to the present compounds for use in the prevention and/or treatment of GPR17 mediated disorders, such as for example a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.